Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.

Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, Kushner RF, Lingvay I, Burguera B, Gajos G, Horn DB, Hramiak IM and 7 more

Show all authors

Jastreboff AM, Kokkinos A, Maeng M, Matos ALSA, Tinahones FJ, Lincoff AM, Ryan DH

Diabetes care1 Aug 2024Cited by 68 (Europe PMC)

PMID38907683PMCIDPMC11282386DOI10.2337/dc24-0491PepBankPUB-38907683

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease but without diabetes, HbA1c was lower with semaglutide than with placebo throughout the study.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, semaglutide kept HbA1c lower than placebo throughout the study.
Peptide
Semaglutide
Outcome
DecreaseHbA1c difference over time
Study
n = 17,604
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Measurements
HbA1c mean difference
−0.32 percentage points
semaglutide versus placebo
Source sentences
Summary
with a mean difference of -0.32 percentage points (95% CI -0.33 to -0.30; -3.49 mmol/mol [-3.66 to -3.32]) and with the difference favoring semaglutide throughout the study (P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768301
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease but without diabetes, HbA1c rose after the 20-week nadir at a similar rate in both arms.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, HbA1c rose after week 20 at a similar rate on semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeHbA1c rise after nadir at 20 weeks
Study
n = 17,604
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Source sentences
Summary
In both treatment arms mean nadir HbA1c for participants was at 20 weeks. Thereafter, HbA1c increased similarly in both arms, with a mean difference of -0.32 percentage points (95% CI -0.33 to -0.30; -3.49 mmol/mol [-3.66 to -3.32]) and with the difference favoring semaglutide throughout the study (P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768302
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease but without diabetes, body weight was 8.9% lower with semaglutide than with placebo after it plateaued at 65 weeks.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, body weight was lower with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight difference
Study
n = 17,604
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Measurements
Body weight difference
8.9%
semaglutide versus placebo
Source sentences
Summary
Body weight plateaued at 65 weeks and was 8.9% lower with semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768303
04HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease but without diabetes, more participants on semaglutide than on placebo were normoglycemic at week 156.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, more people on semaglutide than placebo had normal blood sugar at week 156.
Peptide
Semaglutide
Outcome
IncreaseProportion normoglycemic at week 156
Study
n = 17,604
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Measurements
Normoglycemic proportion
69.5%
semaglutide
Normoglycemic proportion
35.8%
placebo
Source sentences
Summary
At week 156, a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001)
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768304
05HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease but without diabetes, a smaller proportion on semaglutide than on placebo had biochemical diabetes by week 156.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, fewer people on semaglutide than placebo reached the blood sugar range of diabetes.
Peptide
Semaglutide
Outcome
DecreaseProportion with biochemical diabetes by week 156
Study
n = 17,604
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Measurements
Biochemical diabetes proportion
1.5%
semaglutide
Biochemical diabetes proportion
6.9%
placebo
Source sentences
Summary
a smaller proportion had biochemical diabetes by week 156 (1.5% vs. 6.9%; P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768305
06HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease but without diabetes, the number needed to treat with semaglutide to prevent one case of diabetes was 18.5.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, about 18.5 people needed semaglutide to prevent one case of diabetes.
Peptide
Semaglutide
Outcome
Not applicableNumber needed to treat to prevent diabetes
Study
n = 17,604
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Measurements
Number needed to treat
18.5 persons
prevent a case of diabetes
Source sentences
Summary
The number needed to treat was 18.5 to prevent a case of diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768306
07HumanRandomized controlled trialMechanism
In adults with overweight or obesity and cardiovascular disease but without diabetes, the size of weight reduction mediated 24.5% of progression and 27.1% of regression of glycemia with semaglutide.
In plain wordsIn adults with overweight or obesity and heart disease but no diabetes, weight loss explained about a quarter of the glycemic effects of semaglutide.
Peptide
Semaglutide
Outcome
Not applicableWeight reduction as mediator of glycemic regression and progression
Study
n = 17,604
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg weekly · subcutaneous · 152 weeks (mean exposure)As given in this study (human).
Measurements
Mediated by weight reduction, progression
24.5%
semaglutide
Mediated by weight reduction, regression
27.1%
semaglutide
Source sentences
Summary
with the magnitude of weight reduction important in mediating 24.5% of progression and 27.1% of regression.
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicenter, double-blind trial, participants aged ≥45 years, with BMI ≥27 kg/m2, and with preexisting cardiovascular disease but without diabetes (HbA1c <6.5%) were randomized to receive subcutaneous semaglutide (2.4 mg weekly) or placebo.
Summary · context
Of 17,604 participants, 8,803 were assigned to semaglutide and 8,801 to placebo.
Report a problemFND-3890768307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07654062

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Shandong Provincial Hospitaln = 150est. Jul 2026 to est. Jul 2029

Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance (Prediabetes)

Trial page ClinicalTrials.govUpdated 17 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.